Former relevant facts
Relevant Facts until February 8th, 2020.
- 2019 12 30 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 12 23 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 12 16 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 12 09 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 12 02 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 11 25 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 11 18 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 11 11 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 11 04 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 10 28 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 10 21 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 10 14 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 10 07 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 09 30 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 09 23 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 09 16 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 09 09 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 09 02 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 08 19 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 08 05 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 07 29 – Reig Jofre reports the acquisition within the Temporary Share Buy-back Program (PDF)
- 2019 07 25 – Reig Jofre closes the first half of 2019 with a sales growth of 3% and EBITDA of 6% (PDF)
- 2019 07 22 – First tranche of the second share buyback program (PDF)
- 2019 07 01 – Reig Jofre acquires Bioibérica’s portfolio of finished pharmaceutical and nutraceutical products (PDF)
- 2019 06 21 – Start date of trading for the new shares resulting from the capital increase (PDF)
- 2019 06 17 – Reig Jofre informs on the results of the increase of the share capital (PDF)
- 2019 06 13 – Reig Jofre informs on the increase of the Company’s share capital (PDF)
- 2019 06 12 – Reig Jofre informs on the start date of the trading of the new shares within its scrip dividend (PDF)
- 2019 05 31 – Reig Jofre informs on the bonus-shares capital increase and the new shares to be issued (PDF)
- 2019 05 06 – Reig Jofre informs on the execution of the scrip dividend (PDF)
- 2019 04 25 – Reig Jofre informs on the conditions of the scrip dividend (PDF)
- 2019 04 25 – Reig Jofre informs on the resolutions adopted in 2019 Shareholders’ Meeting (PDF)
- 2019 03 25 – Reig Jofre convenes the Ordinary General Shareholders’ Meeting (PDF)
- 2019 03 25 – Reig Jofre informs on the convening of its 2019 General Shareholders´ Meeting (PDF)
- 2019 02 28 – Results preview: Year 2018 (PDF)
- 2019 01 23 – Publication schedule for 2019 results (PDF)
- 2018 12 03 – Transactions within the shares buyback program (PDF)
- 2018 11 26 – Transactions within the shares buyback program (PDF)
- 2018 11 19 – Transactions within the shares buyback program (PDF)
- 2018 11 12 – Transactions within the shares buyback program (PDF)
- 2018 11 05 – Transactions within the shares buyback program (PDF)
- 2018 10 29 – Transactions within the shares buyback program (PDF)
- 2018 10 22 – Transactions within the shares buyback program (PDF)
- 2018 10 15 – Transactions within the shares buyback program (PDF)
- 2018 10 08 – Transactions within the shares buyback program (PDF)
- 2018 09 28 – Transactions within the shares buyback program (PDF)
- 2018 09 24 – Transactions within the shares buyback program (PDF)
- 2018 09 17 – Transactions within the shares buyback program (PDF)
- 2018 09 10 – Transactions within the shares buyback program (PDF)
- 2018 09 06 – Reig Jofre informs on the launch of Remikaf in Indonesia (PDF)
- 2018 09 03 – Transactions within the shares buyback program (PDF)
- 2018 08 27 – Transactions within the shares buyback program (PDF)
- 2018 08 20 – Transactions within the shares buyback program (PDF)
- 2018 08 03 – Transactions within the shares buyback program (PDF)
- 2018 08 03 – Start of the trading of the new shares following the scrip dividend (PDF)
- 2018 07 30 – Transactions within the shares buyback program (PDF)
- 2018 07 25 – Reig Jofre informs on the start of the third Temporary Share Buyback Program (PDF)
- 2018 07 17 – Scrip dividend: bonus-shares capital increase and new shares to be issued (PDF)
- 2018 06 27 – Forté Pharma strengthens its leadership in weight control in France (PDF)
- 2018 06 21 – Reig Jofre informs on the start of coverage through three equity research reports (PDF)
- 2018 06 14 – Scrip dividend: beginning of the trading period of the allotment rights (PDF)
- 2018 06 07 – Remuneration through the scrip dividend or flexible dividend (PDF)
- 2018 05 03 – Resolutions on the general shareholders’ meeting (PDF)
- 2018 04 09 – Reig Jofre informs on the € 30M investment plan to expand its injectable products plant of Barcelona (PDF)
- 2018 03 23 – Reig Jofre convenes the Ordinary General Shareholders’ Meeting (PDF)
- 2018 03 23 – Reig Jofre and Leanbio create the joint venture Syna Therapeutics for the development of biosimilar products (PDF)
- 2018 02 20 – Reig Jofre informs on the presentation of 2017 results (PDF)
- 2018 01 26 – Publication schedule for 2018 results (PDF)
- 2018 01 24 – Launch in France of a new nutritional supplement of Forté Pharma (PDF)
- 2018 01 05 – Transactions within the shares buyback program (PDF)
- 2018 01 03 – Transactions within the shares buyback program (PDF)
- 2017 12 29 – Administrative merger by absorption (PDF)
- 2017 12 15 – Transactions within the shares buyback program (PDF)
- 2017 12 11 – Transactions within the shares buyback program (PDF)
- 2017 12 01 – Transactions within the shares buyback program (PDF)
- 2017 11 13 – Appointment of Alain Boutboul as General Manager of Forté Pharma (PDF)
- 2017 11 10 – Appointment of Mr. Alejandro Garcia Reig, as Vice President of Reig Jofre (PDF)
- 2017 11 07 – Transactions within the shares buyback program (PDF)
- 2017 10 31 – Reig Jofre informs on the expansion of the product portfolio of Forté Pharma (PDF)
- 2017 10 26 – Appointments at the head of the corporate and financial management of the Company (PDF)
- 2017 10 24 – Transactions within the shares buyback program (PDF)
- 2017 10 24 – Reig Jofre informs on the first social-health research worldwide on the use of seawaters in respiratory tract diseases (PDF)
- 2017 09 10 – Transactions within the shares buyback program (PDF)
- 2017 09 26 – Transactions within the shares buyback program (PDF)
- 2017 09 13 – Reig Jofre informs on the launch of Otospray (PDF)
- 2017 09 07 – Admission to trading of the new shares from the scrip dividend (PDF)
- 2017 09 06 – New commercial activity in the Philippines (PDF)
- 2017 09 04 – Transactions within the shares buyback program (PDF)
- 2017 08 22 – Transactions within the shares buyback program (PDF)
- 2017 07 25 – Reig Jofre informs about the new shares (PDF)
- 2017 07 24 – Transactions within the shares buyback program (PDF)
- 2017 07 18 – Transactions within the shares buyback program (PDF)
- 2017 07 10 – Transactions within the shares buyback program (PDF)
- 2017 07 05 – Transactions within the liquidity contract in Q2 2017 (PDF)
- 2017 07 04 – Reig Jofre informs on the end of the commitments between the Company and Naturex SA (PDF)
- 2017 07 03 – Reig Jofre informs about its scrip dividend (PDF)
- 2017 06 30 – Reig Jofre informs about second shares buy-back program (PDF)
- 2017 06 15 – Begining of the trading period of free allotment rights (PDF)
- 2017 06 08 – Conditions for the execution of the capital increase through the scrip dividend or flexible dividend (PDF)
- 2017 06 08 – Resolutions on the general shareholders’ meeting (PDF)
- 2017 05 03 – Convening of the Ordinary and Extraordinary General Shareholders’ Meeting (PDF)
- 2017 05 03 – Reig Jofre, strategic partner in the stabilization and production of the first veterinary vaccine against Leishmaniasis (PDF)
- 2017 04 06 – Transactions within the liquidity contract in Q1 2017 (PDF)
- 2017 03 30 – Reig Jofre informs on the inauguration of a new development and quality control laboratory (PDF)
- 2017 03 23 – Reig Jofre informs on the marketing of three new injectable products for hospitals (PDF)
- 2017 03 16 – Reig Jofre informs on the involvement with emerging biotech companies and research centers (PDF)
- 2017 02 23 – Reig Jofre informs on the public deed of capital reduction (PDF)
- 2017 02 20 – Reig Jofre informs on the presentation of 2016 results (PDF)
- 2017 02 15 – Reig Jofre launches a new product development in the dermatology area (PDF)
- 2017 02 10 – Forte Pharma honored in Hong Kong with the award “Health Wellness Beauty 2016” (PDF)
- 2017 01 30 – Publication schedule for 2017 results (PDF)
- 2017 01 09 – Transactions within the liquidity contract in Q4 2016 (PDF)
- 2017 01 03 – Transactions within the shares buyback program (PDF)
- 2016 12 27 – Transactions within the shares buyback program (PDF)
- 2016 12 20 – Transactions within the shares buyback program (PDF)
- 2016 11 23 – Transactions within the shares buyback program (PDF)
- 2016 11 14 – Transactions within the shares buyback program (PDF)
- 2016 10 25 – Transactions within the shares buyback program (PDF)
- 2016 10 18 – Transactions within the shares buyback program (PDF)
- 2016 10 11 – Transactions within the shares buyback program (PDF)
- 2016 10 03 – Transactions related to the liquidity contract (PDF)
- 2016 10 03 – Transactions within the shares buyback program (PDF)
- 2016 09 26 – Transactions within the shares buyback program (PDF)
- 2016 09 20 – Transactions within the shares buyback program (PDF)
- 2016 09 13 – Transactions within the shares buyback program (PDF)
- 2016 09 06 – Transactions within the shares buyback program (PDF)
- 2016 08 08 – Equity reorganisation (PDF)
- 2016 07 25 – Program of Shares Buyback (PDF)
- 2017 07 22 – Reig Jofre strengthens its workforce and exceeds 910 employees (PDF)
- 2016 07 08 – Transactions within the liquidity contract in Q2 2016 (PDF)
- 2016 06 23 – Resolutions on the general shareholders’ meeting (PDF)
- 2016 06 07 – Allocation of treasury stock to the acquisition of Biotech Geadic
- 2016 05 21 – Convening of the Ordinary and Extraordinary General Shareholders’ Meeting
- 2016 05 20 – Reformulation of the individual and consolidated financial statements for the year 2015
- 2016 04 06 – Transactions within the liquidity contract in Q1 2016
- 2016 02 29 – Results preview: Year 2015
- 2016 02 23 – Reig Jofre certified by the Japanese agency for the manufacture of a sterile injectable for hospital use
- 2016 02 17 – Reig Jofre will present 2015 results
- 2016 02 02 – Reig Jofre strengthens its portfolio of sterile injectable products with the acquisition of a sodium heparin
- 2016 01 25 – Schedule of 2016 results releases2016 01 20 – Reig Jofre strengthens its Respiratory/ENT range with the exclusivity license for Spain of Sterimar®
- 2016 01 04 – New liquidity contract with Solventis AV SA
- 2015 12 21 – Notification of the member state of origin (PDF)
- 2015 12 18 – Changes in the Board of Directors (PDF)
- 2015 11 16 – Treasury stock transactions 9M 2015 (PDF)
- 2015 11 11 – Appointment of Frederic Dingeon as head of the antibiotics development and production business unit (PDF)
- 2015 10 30 – Reorganization of the delegated committees of the Board of Directors (PDF)
- 2015 10 15 – Reig Jofre starts national and international presentation roadshow (PDF)
- 2015 09 22 – Execution of the cancellation and consolidation of shares (reverse split) (PDF)
- 2015 09 17 – Collaboration agreement with the biotechnological company Manremyc (PDF)
- 2015 09 15 – Clarification on the reverse split date (PDF)
- 2015 08 24 – Resignation of Natra from the board of directors (PDF)
- 2015 08 17 – Treasury stock transactions 6M 2015 (PDF)
- 2015 07 31 – Implementation procedures of the reverse split (PDF)
- 2015 07 27 – Reig Jofre increases capital for the entry of Cofides into the share capital of Reig Jofre UK Ltd. (PDF)
- 2015 07 27 – Cofides supports Reig Jofre international development (PDF)
- 2015 07 14 – Reig Jofre announces conference on the six-month results of 2015 (PDF)
- 2015 06 22 – Schedule of the reverse split (PDF)
- 2015 06 12 – Resolutions on the general shareholders’ meeting (PDF)
- 2015 05 18 – Treasury stock operations 3M 2015 (PDF)
- 2015 05 11 – Convening of General Shareholders’ Meeting 2015 (PDF)
- 2015 04 14 – Treasury stock operations Q1 2015 (PDF)
- 2015 04 08 – Acquisition of marketing authorisations in United Kingdom (PDF)
- 2015 03 28 – Answers to unaddressed questions from 2014 results webcast (PDF)
- 2015 03 23 – Documentation of the conference presentation on 2014 pro forma results (PDF)
- 2015 03 18 – Schedule of 2015 results releases (PDF)
- 2015 03 12 – Conference announcement on 2014 proforma results (PDF)
- 2015 03 08 – Commercial agreement in Japan (PDF)
- 2015 02 25 – Release by the Board of Directors regarding the sharp rise of RJF trading price (PDF)
- 2015 02 18 – New corporate website and image (PDF)
- 2015 02 16 – Conclusion of requirements regarding the merger between Reig Jofre and Natraceutical (PDF)
- 2015 02 13 – Liquidity contract (PDF)
- 2015 02 12 – Listing of new shares and change of trading ticker (PDF)
- 2015 02 03 – Register of the merger in the Commercial Registry of Barcelona (PDF)
- 2015 01 16 – Appointment of Chairman and CEO and constitution of delegate committees (PDF)
- 2014 12 31 Register of public deed of the merger with Laboratorio Reig Jofre SA (PDF)
- 2014 12 18 Execution of public deed of the merger with Laboratorio Reig Jofre SA (PDF)
- 2014 12 01 Request for the exemption of TOB (PDF)
- 2014 12 01 End period of opposition from creditors (PDF)
- 2014 10 29 Publication of merger announcements with Laboratorio Reig Jofre (PDF)
- 2014 10 24 Resolutions of the General Extraordinary Shareholders’ Meeting (PDF)
- 2014 10 22 Confirmation of the call for the General Extraordinary Shareholders’ Meeting (PDF)
- 2014 10 21 Pro forma financial statements as of June 30, 2014 (PDF)
- 2010 10 15 Documents of the presentation event on the merger project with Laboratorio Reig Jofre (PDF)
- 2014 09 30 Announcement of public presentations on the merger project with Laboratorio Reig Jofre (PDF)
- 2014 09 22 Convening of the Extraordinary General Shareholders’ Meeting (PDF)
- 2014 07 01 Resolutions of the General Shareholders’ Meeting (PDF)
- 2014 06 27 Date change of the 2014 first half results (PDF)
- 2014 06 26 Merger between Natraceutical and Laboratorio Reig Jofre (PDF)
- 2014 06 26 Merger project between Natraceutical and Laboratorio Reig Jofre (PDF)
- 2014 06 26 Merger protocol between Natraceutical and Laboratorio Reig Jofre (PDF)
- 2014 05 23 Convening of the Shareholders’ General Meeting 2014 (PDF)
- 2014 04 24 Resignation of Felix Revuelta as member of the board of directors (PDF)
- 2014 03 04 Resignation of director Natra, SA and appointment of Galo Álvarez (PDF)
- 2014 01 21 Results release schedule for 2014 (PDF)
- 2014 01 10 Resignation of Ibersuizas and Mª Teresa Lozano from the board of directors (PDF)
- 2012 12 18 Resignation of director Mª Jesús Arregui and appointment of Juan I. Egaña (PDF)
- 2012 12 05 Full syndicated debt redemption (PDF)
- 2012 07 02 Resolutions adopted at the Shareholders General Meeting 2012 (PDF)
- 2012 05 16 Convening of the General Shareholders’ Meeting 2012 (PDF)
- 2012 03 07 Resignation of director Eric Bendelac and appointment of Ibersuizas Alfa, S.L. (PDF)
- 2011 11 02 Pending execution agreements between Natraceutical and Naturex (PDF)
- 2011 03 31 Resignation of the chairman Javier Adserà and other changes in the board of directors (PDF)
- 2011 03 08 Final decision on the call option on Natraceutical (PDF)
- 2011 02 18 Change of director representing BBK at the board of directors (PDF)